Chester County News and Community Website
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), headquartered in West Chester, PA, is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. For more information, visit www.verrica.com.
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled compelling new data from its Phase 2 study of VP-315, a first-in-class oncolytic peptide immunotherapy, showing strong local immune activation …
New Cancer Data Hints at a Surgery-Free Future — Verrica’s VP-315 Shows Big Promise Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has provided positive feedback supporting …
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will present new data on its investigational oncolytic peptide therapy, VP-315, for the treatment of basal cell carcinoma …
Verrica Pharmaceuticals to Present Phase 2 Data on VP-315 at Major Immunotherapy Conference Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that its partner Torii Pharmaceutical Co. Ltd., now a subsidiary of Shionogi & Co., Ltd., has received approval from Japan’s …
Verrica Secures $10 Million Milestone as YCANTH Wins Approval in Japan Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that President and Chief Executive Officer Jayson Rieger, PhD, MBA, will present at the H.C. Wainwright 27th Annual Global Investment …
Verrica Pharmaceuticals CEO to Present at H.C. Wainwright Global Investment Conference Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported second-quarter 2025 revenue of $12.7 million, driven by continued commercial momentum for its lead product, YCANTH®, and milestone payments from …
Verrica Pharmaceuticals Posts Strong Q2 Growth, Advances Basal Cell Carcinoma Program Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced a significant surge in demand for its lead product, YCANTH®, in the second quarter of 2025, reporting 13,434 dispensed applicator …
Verrica Reports Strong Q2 Growth as YCANTH Demand Accelerates Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced an amended collaboration and licensing agreement with Torii Pharmaceutical Co. Ltd. to initiate a global Phase 3 clinical trial …
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that its President and Chief Executive Officer, Jayson Rieger, PhD, MBA, will speak at the prestigious Jefferies Global Healthcare …
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced significant progress in the first quarter of 2025, reporting $3.4 million in revenue from YCANTH. This figure reflects a …
Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline Read More